With that currently being claimed, with no human trials there's no way to really evaluate how much YK11 can inhibit Myostatin in people (if in the slightest degree), and if there is a dosage that might equate to precisely the same volume of Myostatin inhibition that a genetic anomaly which has a gene mutation has.YK11 differs from traditional SARMs